scbmtБИОМЕДИЦИНАJournal Biomed2074-59822713-0428Scientific center of biomedical technologies of Federal Medical and Biological Agencyscbmt-986Research ArticleСтатьиСостояние клеточной β-адренорецепции при артериальной гипертонии и ее модификация на фоне лечения различными формами
β-адреноблокатора метопрололаМанешинаО. А.noemail@neicon.ruЛеоноваМ. В.noemail@neicon.ruБелоусовЮ. Б.noemail@neicon.ruДуханинА. С.noemail@neicon.ruГОУ ВПО РГМУ, МоскваRussian Federation200613022020135052Copyright © Манешина О.А., Леонова М.В., Белоусов Ю.Б., Духанин А.С., 20202020Манешина О.А., Леонова М.В., Белоусов Ю.Б., Духанин А.С.Манешина О.А., Леонова М.В., Белоусов Ю.Б., Духанин А.С.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.scbmt.ru/jour/article/view/986Β-адренорецепторыартериальная гипертонияβ-адреноблокаторыReferencesLücker P, Moore G, Wiselgren I, et al. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990; 30 (Suppl): S17-27Lücker P, Moore G, Wiselgren I, et al. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990; 30 (Suppl): S17-27Plosker GL, Clissold SP. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs 1992; 43 (3): 382-414.Plosker GL, Clissold SP. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs 1992; 43 (3): 382-414.Zineh I <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Zineh+I%22%5BAuthor%5D>, Beitelshees AL <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Beitelshees+AL%22%5BAuthor%5D>, Gaedigk A <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Gaedigk+A%22%5BAuthor%5D>, Walker JR <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Walker+JR%22%5BAuthor%5D>, Pauly DF <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Pauly+DF%22%5BAuthor%5D>, Eberst K <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Eberst+K%22%5BAuthor%5D>, Leeder JS <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Leeder+JS%22%5BAuthor%5D>, Phillips MS <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Phillips+MS%22%5BAuthor%5D>, Gelfand CA <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Gelfand+CA%22%5BAuthor%5D>, Johnson JA <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Johnson+JA%22%5BAuthor%5D>. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. <javascript:AL_get(this,%20'jour',%20'Clin%20Pharmacol%20Ther.');> 2004 Dec;76(6):536-44.Zineh I <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Zineh+I%22%5BAuthor%5D>, Beitelshees AL <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Beitelshees+AL%22%5BAuthor%5D>, Gaedigk A <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Gaedigk+A%22%5BAuthor%5D>, Walker JR <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Walker+JR%22%5BAuthor%5D>, Pauly DF <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Pauly+DF%22%5BAuthor%5D>, Eberst K <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Eberst+K%22%5BAuthor%5D>, Leeder JS <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Leeder+JS%22%5BAuthor%5D>, Phillips MS <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Phillips+MS%22%5BAuthor%5D>, Gelfand CA <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Gelfand+CA%22%5BAuthor%5D>, Johnson JA <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&itool=PubMed_Abstract&term=%22Johnson+JA%22%5BAuthor%5D>. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. <javascript:AL_get(this,%20'jour',%20'Clin%20Pharmacol%20Ther.');> 2004 Dec;76(6):536-44.
The authors declare that there are no conflicts of interest present.